Pipeline — registered trials by phase
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
— · Colorectal Cancer · Recruiting · est. 2027-02
Tempus Priority Study: A Pan-tumor Observational Study
— · Breast Cancer, Prostate Cancer, Bladder Cancer · Active Not Recruiting · est. 2026-10-19
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
— · Aortic Valve Stenosis, Mitral Regurgitation · Completed · est. 2025-12-01
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
— · Cancer · Recruiting · est. 2029-06-01
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
— · Small Cell Lung Cancer · Recruiting · est. 2029-03
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
— · Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL) · Recruiting · est. 2034-11
Umbrella Study for Analysis of Data Related to Patients With Cancer
— · Cancer · Completed · est. 2025-07-01
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
— · Head and Neck Squamous Cell Carcinoma · Recruiting · est. 2028-03-01
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
— · Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer · Recruiting · est. 2032-12
GEMINI-NSCLC: NSCLC Biomarker Study
— · Non-Small Cell Lung Cancer · Recruiting · est. 2029-06
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
— · Pulmonary Hypertension, Interstitial Lung Disease (ILD) · Recruiting · est. 2028-05
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
— · Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia · Recruiting · est. 2031-07
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Tempus AI is lead sponsor; 12 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- S-4/A2026-10-02S-4/A
- 4252026-09-15425
- S-42026-08-31S-4
- 10-Q2026-07-30Quarterly report
- 8-K2026-07-30Current report (material event)
- SCHEDULE 13D/A2026-07-21SCHEDULE 13D/A
- 4252026-07-20425
- 4252026-07-20425
- 4252026-07-20425
- 4252026-07-20425
- 8-K2026-07-20Current report (material event)
- 4252026-07-20425
- 8-K2026-07-20Current report (material event)
- 8-K2026-05-22Current report (material event)
- 8-K2026-05-13Current report (material event)
- SCHEDULE 13G/A2026-05-07SCHEDULE 13G/A
- 10-Q2026-05-05Quarterly report
- 8-K2026-05-05Current report (material event)
- ARS2026-04-07Annual report to holders
- DEFA14A2026-04-07DEFA14A
- DEF 14A2026-04-07Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- SCHEDULE 13G2026-03-06SCHEDULE 13G
- S-82026-02-24Employee stock plan
- 10-K2026-02-24Annual report
- 8-K2026-02-24Current report (material event)
- SCHEDULE 13G/A2026-02-10SCHEDULE 13G/A
- 8-K2026-01-12Current report (material event)
- SCHEDULE 13G/A2025-11-13SCHEDULE 13G/A
- SCHEDULE 13G/A2025-11-12SCHEDULE 13G/A
- 10-Q2025-11-04Quarterly report
- 8-K2025-11-04Current report (material event)
- SCHEDULE 13G2025-10-31SCHEDULE 13G
- SCHEDULE 13D/A2025-09-12SCHEDULE 13D/A
- 8-K2025-08-27Current report (material event)
- 424B72025-08-27424B7
- DEF 14C2025-08-18DEF 14C
- PRE 14C2025-08-08PRE 14C
- S-8 POS2025-08-08S-8 POS
- S-8 POS2025-08-08S-8 POS
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.